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BACKGROUND: Portal vein tumour thrombus (PVTT) is highly associated with the progression and metastasis of hepatocellular
carcinoma (HCC). However, there are no appropriate cell models of PVTT with which to study the biological and physiological
characteristics of PVTT.
METHODS: Primary cell culture was performed by the use of a successive xenograft line called PVTT-#1, which was obtained from a
60-year-old male HCC patient accompanied by PVTT.
RESULTS: A successive cell line named CSQT-2 was established. The cell line showed aggressive phenotypes in terms of cell growth,
survival, migration, xenograft and metastasis. Moreover, an orthotopic transplantation assay showed that PVTT can be generated in
nude mice when CSQT-2 cells were inoculated in the liver and that it shows a typical migratory tendency in the vascular branches of
portal vein. Moreover, the established CSQT-2 cells also showed varied expression of tumour-initiating cell (TIC) markers such as
CD133, CD90 and EpCAM.
CONCLUSION: Establishment of CSQT-2 may provide a suitable model with which to investigate the molecular mechanisms of
PVTT-related HCC.
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Hepatocellular carcinoma (HCC) ranks as the fifth most common
cancer around the world, (Parkin, 2006; Portolani et al, 2006;
Yamane and Weber, 2009), and it is one of the major health
problems worldwide. Currently, the geographical areas bearing the
highest incidence are eastern Asia as well as middle and western
Africa, whereas the incidence is increasing in North and South
Americas (Bosch et al, 2005; Michielsen et al, 2005; Chen et al,
2006). In addition, the mortality due to liver cancer has shown the
fastest rate of increase in the United States, even though overall
cancer-related mortality has been declining (www.seer.cancer.gov).
In fact, liver cancer metastasis and recurrence are known to
be highly lethal (Kornek et al, 2008). Unfortunately, the poor
understanding of the development of HCC metastasis has been the
main obstacle for the improvement of HCC therapy (Shuqun et al,
2004; Sun et al, 2007; Amarapurkar et al, 2008; Lim et al, 2008;
Ramaiah and Rittling, 2008). Portal vein tumour thrombus (PVTT)
arising from the invasion of HCC cells into the portal vein, is a
special type of HCC metastasis (Shuqun et al, 2007; Zhou et al,
2008). Chau et al (2003) has reported that the incidence of
microscopic tumour thrombi is about 49.6%. As a well-known
poor prognostic factor, PVTT markedly deteriorates the hepatic
function and correlates with greater recurrence and intrahepatic
metastasis (Li et al, 2009). Nevertheless, the aetiology of PVTT in
HCC metastasis is largely unknown (Shuqun et al, 2006; Inoue
et al, 2009; Inui et al, 2009). The lack of an experimental model
may be responsible for our poor understanding of the mechanism
through, which PVTT is involved in HCC metastasis (Takizawa
et al, 2007; Liang et al, 2008). However, in many cases, the primary
cultures of PVTT cells are not able to survive and thrive for a long
time (Choi et al, 2008). Therefore, the aim of this study was to
establish a PVTT-originated HCC cell line that has characteristics
of PVTT. We have successfully developed a human PVTT-
originated xenograft model in nude mice, named PVTT-#1
(submitted for publication), which has thrived for generations.
Here, by using the orthotropic tumour of this model, we succeeded
in establishing novel PVTT-originated HCC cell lines that could
contribute to the study of PVTT.
MATERIALS AND METHODS
Experiment design
This experimental protocol was approved by the Institutional
Review Board of the Eastern Hepatobiliary Hospital. Informed
consent was obtained from the patient.
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Tumour tissue was obtained from a 60-year-old male patient from
northwest China who was diagnosed with HCC accompanied by
PVTT. His oncological family history was unknown. He had no
history of operations. Blood tests showed an AST level of 86Ul
–1,
a-fetoprotein level of 258ngml
–1, carcinoembryonic antigen
level of 2.8ngml
–1 and positivity for HBsAg. Before operation,
the patient complained of tender upper right abdominal pain.
A computerised-tomography showed a lesion (10cm 11cm) in
the right lobe of the liver and a PVTT invasion to the right branch
of the portal vein. We have performed a partial liver resection plus
thrombectomy on the patient. Pathological evaluations confirmed
that both HCC and PVTT showed mid-level differentiation on
the Edmondson criteria and that the liver cirrhosis was mild.
The patient died of lung metastasis 3 months after hepatectomy.
Animals and cell lines
We obtained 6-week-old male BALB/c nude mice from the
Institute of Nutritional Sciences, Chinese Academy of Science,
and they were maintained in a specific pathogen-free condition.
The study protocol on mice was approved by the Shanghai Medical
Experimental Animal Care Commission. The 7702 liver cancer
cell lines were purchased from the Cell Bank of Type Culture
Collection of the Shanghai Institute of Cell Biology, Chinese
Academy of Sciences. They were cultured in RPMI 1640, and
supplemented with 10% fetal bovine serum, 10unitsml
–1 peni-
cillin, and 10unitsml
–1 streptomycin, at 371C in a humidified
atmosphere containing 5% CO2. MHCC97-H and MHCC97-L cell
lines were purchased from the Liver Cancer Institute of Fudan
University, Shanghai. They were cultured in DMEM and supple-
mented with 10% fetal bovine serum, 10unitsml
–1 penicillin and
10unitsml
–1 streptomycin.
Antibodies and reagents
Rabbit anti-human phospho-Akt and EGFR antibodies were
brought from Cell Signal. Mouse monoclonal anti-human b-Actin
antibody was purchased from Santa Cruz Biotechnology. APC-
labelled anti-CD133 and FITC-labelled anti-CD90, EpCAM anti-
bodies were brought from MACS.
Establishment of the PVTT xenograft model
The establishment of the PVTT xenograft model was performed
as described by Sun et al (1996), with slight modifications. We
initially developed a successive tumour line in nude mice using
the patient’s portal vein tumour thrombus specimen. When the
patient’s PVTT specimen was obtained, it was cut into pieces with
dimensions of about 2mm 2mm 2mm that were implanted
into the liver of each of the six nude mice. Once the orthotopic
tumour was able to survive and developed into a gross tumour
bulk, it was removed and cut into pieces of about 2mm 
2mm 2mm in dimension, which were implanted into the liver
and subcutaneously (in the armpit and groin) of each nude mouse,
using the method described previously. At last, we succeeded in
establishing the xenograft model named PVTT-#1.
Culture of primary and successive cell lines
Several attempts at primary cultures were made using the
orthotropic tumour derived from the PVTT-#1 xenograft model
described above. These xenografts were removed and used for
primary culture in vitro by different culture methods as described
by Tian et al (1999). In the end, we observed that the most suitable
environment for cell culture was in DMEM with 10% fetal bovine
serum at 371C in a humidified atmosphere with 5% carbon dioxide
in vitro. The successive HCC cell line that passed more than 100
generations was named as CSQT-2.
RNA Extraction and RT PCR assay
Total RNA was isolated with TRIzol reagent (Invitrogen) from
CSQT-2 cell lines and from tissues of PVTT patients after their
informed consent was obtained according to institutional regula-
tory requirements. The RNA samples were separated in 2% agarose
gels containing ethidium bromide, and their quality was then
determined by visibility of the 18 S and 28 S RNA bands under UV
light. A total of 2mg of high quality RNA was processed directly to
cDNA with the reverse transcription kit (Promega, Madison, WI,
USA), following the manufacturer’s instructions. The PCR
procedure used for the detection of human cIAP1, EGFR, Integrin
b-5, uPAR, cMet and b-actin was slightly modified from the
procedure described by Tian et al (1999).
DNA isolation
Cultured cells (1 10
6) were thoroughly homogenised in 400ml
DNA denature solution, then incubated in 100ml 5% SDS (mV
–1)
buffer containing 20ml RNAase and 20ml proteinase K at 371C for
24h. The DNA was extracted with phenol–chloroform. Extracted
DNA was precipitated with ethanol and resuspended in distilled
water.
Cytogenic analysis
Chromosome preparation and G-banding were performed as
Seabright (1971) described with slight modifications. Briefly,
colcemid was added to cell cultures at the 60th passage to a final
concentration of 0.25mgml
–1 for 10–15h. Cells were then tryp-
sinised and centrifuged at 1200r.p.m. for 12min. The hypotonic
medium used was 0.075mol potassium chloride for 20min at 371C,
and then the fixative (methanol/glacial acetic acid, 3:1) was
changed three times before slides were made. Some of the slides
were aged at 601C for 8–10h for G-banding. The aged slides were
trypsinised for 3.5min, rinsed in water and stained with Giemsa,
rinsed again, air dried and examined under the microscope. For
C-banding, the rest was soaked in 0.2 N hydrochloric acid for 1h,
and then incubated in 5% Ba(OH)2 at 561C for 10min and rinsed
in water. After that, the slides were re-incubated with 2 SSC
(saline sodium citrate) at 671C for 1–1.5h, rinsed again and
stained with Giemsa.
Western Blot
Cultured cells were washed twice with PBS and lysed in RIPA
buffer for 30min on ice. Cell lysates were clarified by centri-
fugation at 10000g for 15min, and the protein concentration
was determined using the Bradford reagent (Sigma). Total cell
lysates (40mg protein) were separated using 10% SDS–PAGE
gels and electrotransferred onto polyvinylidene difluoride
membranes (Millipore, Bedford, MA, USA). After blockage with
5% milk, the membranes were probed with primary antibodies
at 1:1000 dilutions. The membrane was washed and then
incubated with horseradish peroxidase-conjugated secondary
antibodies for 1h. Immunoreactive proteins were detected
with enhanced chemiluminescence reagents (Pierce, Rockford,
IL, USA) and photographed with Kodak X-Omat blue autoradio-
graphy film.
Cell surface marker expression analysis
Cells (10
6) were trypsinised and suspended in 100ml D-Hank’s
buffer. APC or FITC-labelled cell surface marker-targeted anti-
bodies (CD133, CD90 and EpCAM) (10ml) were added and cells
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D-Hank’s buffer twice, re-suspended in 300ml D-Hank’s buffer and
sent for FACS analysis.
MTT assay
The assay of the cell growth curve was performed as Patterson Jr
MK (1979) described, with slight modifications. Cells were plated
into 96-well plates at 3000 cells per well, cultured in 10% FBS
DMEM for various durations, and the cell numbers were measured
by MTT assay according to the protocol provided by the MTT
manufacturer.
Soft agar assay
Cells were plated in 24-well flat-bottomed plates using a two-layer
soft agar system with 1 10
3 cells per well in a volume of 400ml per
well as described previously (Munker et al, 1986). After 14 days of
incubation, colonies were counted and measured. All the experi-
ments were repeated at least three times using triplicate plates per
experimental point.
Boyden chamber
Boyden chamber (8-mm pore size polycarbonate membrane)
was obtained from Neuroprobe Corp, Bethesda, MD, USA. Cells
(2 10
5) in 0.05ml medium with 1% FBS were placed in the upper
chamber, and the lower chamber was loaded with 0.152ml medium
containing 10% FBS. Cells that migrated to the lower surface of
filters were detected with traditional H&E staining, and five fields
of each well were counted after 4–24h of incubation at 371C with
5% CO2. Three wells were examined for each condition and cell
type, and the experiments were repeated thrice.
Tumourigenicity assay
Cultured cells of CSQT-2 were washed with D-Hank’s solution, and
100000, 10000 or 1000 cells suspended in 100ml of DMEM and
100ml Matrigel were injected into the flanks of 6-week-old male
nude mice purchased from the Shanghai Laboratory Animal
Centre, CAS (Shanghai, China). They were treated in accordance
with the American Association for the Accreditation of Laboratory
Animal Care guidelines. Three mice were used in the groups with
different cell numbers. The resulting tumours were measured once
a week before the mice were killed and the tumour volume (mm
3)
was calculated using the standard formula: length width 
height 0.5236.
Orthotopic transplantation
For orthotopic transplantation, obtained specimens were cut into
pieces of about 2mm 2mm 2mm in dimension that were
implanted into the liver and subcutaneously (in the armpit and
groin) of each of the six nude mice, using the method as described
by Sun et al (1996) mentioned above. Once the subcutaneous
tumour reached 1–1.5cm in diameter, it was removed and cut into
pieces of about 2mm 2mm 2mm in dimension that were
implanted into the liver and subcutaneously (in the armpit and
groin) in each of six nude mice, using the methods described
previously.
Luciferase labeling of CSQT-2 cells
Luc2 luciferase-coding region sequence was amplified by PCR and
cloned into the FG12 lentiviral expression vector. FG12-Luc2
construct was transfected into packaging-293T cells for lentivirus
production. CSQT-2 cells were infected by the FG12-Luc2
lentivirus to stably express luciferase gene.
A ab c
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C
Figure 1 Morphology of CSQT-2 cell line. (A) Microphotograph of the cultural cell line CSQT-2 of different passages in culture. a: primary cell, b: Passage 3,
c: Passage 55. (B) Scanning electron microscopy of CSQT-2 cells showing microvilli on cell surface (s.e.m.,  2000). (C) Transmission electron microscopy
of CSQT-2 cell line displaying irregular desmosomes, mitochondrium, ribosomes and nuclei. (TEM,  7500).
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For the experimental metastasis assay, two routes of injection
were used in our experiment. The intracardiac and the intra-
spleen routes. A total of 500000 cells were used in each injection.
The metastatic tumour growth was measured by luciferase
activity detection using the IVIS. Male nude mice were housed
under standard conditions. For intracardiac injections, subcon-
fluent cells were harvested, washed in PBS and resuspended at a
concentration of 1 10
7 cells per ml. BALB/c nude mice were
anaesthetised by intraperitoneal injection of Chloral hydrate
(30mgkg
–1) and were placed in the supine position. After
visualisation of arterial blood flow into the syringe, 5 10
5 cells
were injected into the left ventricle via the third intercostal
space. Successful injections were confirmed by immediate IVIS.
For intrasplenic injections, anaesthetised mice were placed in
the supine position on the nude mice tables. The spleen of the
nude mouse was explored with skin and peritoneal incisions,
and 5 10
5 cells of CSQT-2 were injected into the spleen of
nude mice for metastasis. Metastasis appeared 4 weeks after
injection. Successful injections were confirmed by immediate IVIS.
All animal studies were performed in accordance with the SIBS
Guide for the Care and Use of Laboratory Animals and approved
by the Animal Care and Use Committee, Shanghai Institutes for
Biological Sciences.
RESULTS
Establishment of a HCC cell line
To establish a HCC culture, we first developed a successive tumour
line in nude mice using the patient’s portal vein tumour thrombus
specimen mentioned above. Next, a primary culture was made
using the orthotropic tumour derived from that tumour line.
At last, we succeeded in maintaining the primary cultured cells and
subculturing them for more than 100 generations in DMEM with
10% fetal bovine serum in vitro. This successive HCC cell line was
named as CSQT-2.
Morphology of the HCC cell line CSQT-2
In the initial few passages, CSQT-2 cells formed intact colonies
showing typical epithelial cell shapes (Figure 1A). With successive
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Figure 2 In vitro assay of CSQT-2 cell line. (A) Cell growth of CSQT-2 and MHCC97-H. Both cells were plated in 96-well plate with a concentration of
3000 cells per well. MTT assay was performed each day to depict a growth curve. (B) Cell cycle analysis of CSQT-2. CSQT-2 cells were harvested for FACS
analysis after PI staining. (C) Anchorage-independent growth. CSQT-2 and MHCC97-H cells were plated in 1.0% Agar with 20% FBS complemented for 2
weeks to test the formation of colonies. (D) Cell migration analysis of CSQT-2 and MHCC97-H. Both cells were set for modified Boyden chamber assay to
test the migratory ability.
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shapes, but they moved away from each other and lost the
colony type formation compared with the initial passage
(Figure 1A). Ultrastructurally, the CSQT-2 cells showed intense
microvilli on the cell surfaces, which were probably formed by
the dysregulation of actin and tubulin-based cytoskeleton
(Figure 1B). Upon examination with the transmission electron
microscope, most of the CSQT-2 cells were found to contain
irregular desmosomes, mitochondrium, ribosomes and nuclei
(Figure 1C).
Characteristics of CSQT-2 cell line in vitro
After several passages of in vitro culture, we performed a series
of assays to characterise the CSQT-2 cells in vitro. The cell
growth of CSQT-2 cells was tested using the MTT assay with the
MHCC97-H cells as a positive control (Figure 2A). It was found
that the CSQT-2 cells had a shorter double time in vitro compared
with MHCC97-H cells, which have been known to be fairly
aggressive. The rapid cell growth in the CSQT-2 cells may be
attributed to lower cell apoptosis and more rapid cell cycles. As
shown in Figure 2B, about 50% of the cells were in the S-G2-M
phases (Figure 2B). Moreover, the CSQT-2 cells showed stronger
anchorage-independent growth abilities (Figure 2C). In the
migration assay, it was shown that the migratory capacity of
CSQT-2 cells surpassed that of the MHCC97-H cells (Figure 2D).
Taken together, these results indicated that CSQT-2 cells could be
more intensely metastatic in vivo.
Characteristics of CSQT-2 cell line in vivo
Following the in vitro study, the in vivo behaviour of CSQT-2 cells
was examined. In nude mice, CSQT-2 cells showed stronger
subcutaneous tumourigenicity ability (Figure 3A). By labelling
CSQT-2 cells with the Luc2 reporter gene, we successfully detected
the orthotropic tumour formation in real-time. As shown in
Figure 3B, CSQT-2 cells could generate HCC in immunodeficient
mice. Next, to evaluate the metastatic potential of CSQT-2 cells, we
performed intra-cardiac injections in nude mice, and metastatic
lesions developed in the bone and lymph nodes (Figure 3C).
Similarly, 3 weeks after intra-spleen injection of CSQT-2 cells, liver
metastasis could be found (Figure 3D). PVTT is known to be
frequently associated with the progression of HCC. In our study,
orthotropic implantation of CSQT-2 tumours in the liver of nude
mice generated PVTT sites in the portal vein systems of the host
(Figure 3E). All of the above showed that the CSQT-2 cells
recapitulated the clinical features of malignant HCC.
Identification of the expression of tumour-initiating cell
markers in CSQT-2
It has been reported that HCC probably originated from a few
cancer cells that expressed certain tumour-initiating (TIC) markers
such as CD133, CD90 and EpCAM. It was found that in the early
passages, a small portion of the primary CSQT-2 cells expressed
CD133, whereas CD133-positive cells (Figure 4A) or CD90 cells
(Figure 4B) could not be detected after 30
þ passages. In contrast
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Figure 3 In vivo assay of CSQT-2 cell line. (A) Subcutaneous growth of CSQT-2 tumour. 100000, 10000 or 1000 cells of CSQT-2 were inoculated at the
flanks of nude mice. Three mice were used in each group with different cell numbers. (B) Orthotropic growth of CSQT-2 tumour labeled with luciferase.
CSQT-2 cells labeled with luciferase were first injected into the flank of nude mice. After subcutaneous tumour appeared, it was harvested and inoculated
into the liver of fresh nude mice. The orthotropic tumour growth was measured by luciferase activity detection by IVIS system. (C) Metastatic growth of
CSQT-2 tumour via cardiac injection. 500000 cells of CSQT-2 were injected into the left ventricle of nude mice for metastasis. Shown was the metastasis4
weeks post injection. (D) Metastatic growth of CSQT-2 tumour via intra-spleen injection. 500000 cells of CSQT-2 were injected into the spleen of nude
mice for metastasis. Shown was the metastasis 4 weeks post injection. (E) PVTT formed by CSQT-2 orthotropic tumour. The mouse livers in (B) were
harvested for fixation and H&E staining to detect whether PVTT was formed. Three typical PVTT sections were shown.
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Figure 6 Karyotype analysis of CSQT-2 cell line (passage 60). The karyotype of the CSQT-2 cell line for abnormalities in both the number and structure
in passage 60.
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sto CD133 and CD90 expression, EpCAM positivity in CSQT-2 cells
dramatically increased with more passages (Figure 4C).
Identification of metastasis-related genes in CSQT-2
Cancer metastasis is a complicated process facilitated by the
abnormal expression of metastasis-related genes, such as those
involved in cell proliferation, apoptosis and migration. EGFR was
dramatically overexpressed in CSQT-2 cells, which may contribute
to the rapid tumour growth (Figure 5A and C). Akt, a key regulator
of cell survival, was also hyperphosphorylated in CSQT-2 cells
(Figure 5C), which probably led to the suppression of apoptosis.
Consistent with Akt hyperactivation, cIAP1 expression was also
upregulated in CSQT-2 cells. The HGF–cMet cascade was of great
importance in controlling HCC cell proliferation as well as
metastasis. We found that the expression of cMet was as high as
that of MHCC97-H cells (Figure 5B). In addition, we tested other
metastasis-related genes such as uPAR and some Integrins.
Altogether, many other metastasis-related genes were found to
show dysregulation in CSQT-2 cells (Figure 5).
KARYOTYPE OF THE CSQT-2 CELL LINE
With the help of G-banding staining technology, we analysed the
karyotype of the CSQT-2 cell line for abnormalities in both the
number and structure (Figure 6). The number of chromosomes
in this cell line ranged from 58 to 73 with a median of 67. At
least three significant abnormalities, add(3) (qter-pter::?),
der(4)t(qter-zp14::?) and add(19)(qter-pter::?) were found
invariably in all cells (30/30), In addition, two other variations,
add(15)(?::pter-q24::?) and add(18)(pter-qter::?) were found in
most cells (29 of 30). Some other alterations, 1pter-p12::16qter-
pter, add(2)(qter-pter::?) and add(7)(?::pter-qter::?) were also
found frequently (Tables 1 and 2).
DISCUSSION
Prevention and effective control of metastasis are essential to HCC
therapy, Therefore, it is urgent that we improve our understanding
of the molecular mechanisms of HCC progression and metastasis
(Tang et al, 2004; Wang et al, 2009). As PVTT formation is a
common event in HCC metastasis, it is reasonable and worthwhile
to conduct studies of PVTT-related HCC. For example, although
the significant relationship between PVTT formation and HCC
metastasis has been well documented by many groups, whether
PVTT formation contributes to intrahepatic as well as distant
metastasis of HCC is still not known (Qiu et al, 2008). Alter-
natively, it is also possible that PVTT is merely a consequence of
HCC metastasis (Aldrighetti et al, 2009; Matsumoto et al, 2009).
Another interesting question is how different the PVTT cells are
from their primary ancestors, or how divergent they are compared
with primary HCC cells (Chen and Huang, 2005). However, if a
suitable cell model is not available, it is very difficult to investigate
these questions.
To our knowledge, CSQT-2 is the first HCC portal vein tumour
thrombus-originated cell line, which showed a relatively high
metastatic potential. More importantly, this cell line was able to
generate PVTT in nude mice after orthotropic inoculation. The fact
that CSQT-2 is able to generate PVTT greatly facilitates our
research of PVTT progression. More importantly, it has allowed us
to examine whether the formation of PVTT occurs before extra-
vascular metastasis, which could shed light on the significance of
PVTT. In addition, we could investigate whether extravascular
metastasis of HCC is affected by blocking PVTT formation.
Table 1 Appearing frequency of abnormal chromosomes in 30 karyotype analysed (passage 60)
Extra chromosomes Abnormal chromosomes (markers)
Chromosome  Y+ 2+ 3 + 3  2 4 5 6 M3 M4 M5 M6 M7 M8 M9
Frequency 9 16 16 13 23 16 22 18 27 8 28 30 30 28
Chromosome 7 +7 2  8  9 10 +10 2 +10 3 M10 M11 M13 M14 M15 M16 +Mar16 2
Frequency 15 9 10 9 6 16 6 24 28 16 25 21 10 8
Chromosome  11 12  13  13 2  14 15 +15 2 M18 M19 M20 M21 M22 M23 M24
Frequency 11 18 19 7 16 21 9 12 6 24 9 29 10 18
Chromosome 16 +16 2 +16 4 17 +17 2 18 +18 2 M25 M26 M27 M28 M29 M30 +Mar31 2
Frequency 4 20 6 15 14 9 9 26 10 29 15 30 19 20
Chromosome +18 3 19 +19 2 20 +20 2 21 +22 2 +Mar31 3 +Mar1 2 +Mar2 M12 M17
Frequency 12 18 6 16 8 10 18 10 25 7 3 2
Chromosome +22 3 +Mar1 2 +Mar2 +Mar16 2 +Mar31 2 +Mar31 3
Frequency 10 25 7 10 20 10
Appearing frequency of abnormal chromosomes exceeded 50% of karyotype analysed.
Table 2 Abnormal chromosomes for CSQT-2 cell lines
Chromosomes Markers
M1 dmin
M3(xq ) del(x)(pter-q26:)
M4(der(1)) 1pter-p12::16qter-pter
M5(1q ) del(1)(pter-q23:)
M6(2p+) add(2)(qter-pter::?)
M7(3p+) add(3) (qter-pter::?)
M8(4p ) der(4)t(qter-p14::?)
M9(6q+) add(6) (pter-qter::?)
M10(7q ) del(7)(pter-q33:)
M11(der(7)) add(7)(?::pter-qter::?)
M12(7p ) del(7)(qter-p13:)
M13(8p+) add(8)(qter-pter::?)
M14(9q+) add(9)(pter-qter::q11-qter)
M15(i(9q)) i(9)(q10)
M16(der(10)) add(10)(?::pter-qter::?)
M17(10p ) del(10)(qter-p12:)
M18(i(10q)) i(10)(q10)
M19(der(11)) add(11)(pter-qter::?)
M20(der(12)) der(12)t(qter-p12::?)
M21(i(14q)) i(14)(q10)
M22(der(15)) add(15)(?::pter-q24::?)
M23(der(15;22)) der(15)t(15qter-pter::22q11-qter)
M24(i(16p)) i(16)(p10)
M25(der(16)) add(16)(pter-qter::?)
M26(17q+) add(17)(pter-qter::?)
M27(18q+) add(18)(pter-qter::?)
M28(18q ) del(18)(pter-q21:)
M29(19p+) add(19)(qter-pter::?)
M30(der(22)) der(22)(?::pter-q12:)
M31(22q+) add(22)(pter-q11::?)
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that a cancer mass is built up by a relatively tiny portion of the
total tumour, called cancer stem cells or TIC (Guglielmi et al, 1998;
Bansal and Banerjee, 2009; Kawasaki et al, 2009; Tu et al, 2009).
The previous research on HCC TICs found that we could separate
or enrich HCC TICs through specific staining for cell surface
markers, such as CD133, CD90 and EpCAM (Yang et al, 2008a,b;
Yamashita et al, 2009; Yeh et al, 2009; Yoshikawa et al, 2009; Zhu
et al, 2009). It is intriguing that the CSQT-2 cell line showed no
CD133 or CD90 positivity, even though the corresponding primary
cells contained apparent CD133- and CD90-positive subpopula-
tions, this suggested that these two markers might not be critical in
our cell line. Surprisingly, the whole population of CSQT-2 cells in
the cell line was EpCAM positive. This might explain the strong
xenografting ability of CSQT-2 in nude mice (Yamashita et al,
2008). Furthermore, such observation also raised the possibility
that the TIC marker expression might be different between
primary and portal vein invasive HCC cells. If confirmed, this
would undoubtedly alter our interpretation of the cancer stem cell
theory, and we can establish the HCC cell line from the primary
HCC and the paired PVTT cell line. Once we succeed, the
difference as well as the similarities between these two types of cell
lines could be compared, this will not only broaden our knowledge
of the progression of HCC and PVTT, but it will also allow the
study of the mechanism through which HCC can progress to
PVTT.
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